PMID- 33620716
OWN - NLM
STAT- MEDLINE
DCOM- 20220118
LR  - 20220118
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 44
IP  - 10
DP  - 2021 Oct
TI  - Development and validation of a three-immune-related gene signature prognostic 
      risk model in papillary thyroid carcinoma.
PG  - 2153-2163
LID - 10.1007/s40618-021-01514-7 [doi]
AB  - PURPOSE: Increasing evidence indicates that there is a correlation between 
      papillary thyroid carcinoma (PTC) prognosis and the immune signature. Our goal 
      was to construct a new prognostic tool based on immune genes to achieve more 
      accurate prognosis predictions and earlier diagnoses of PTC. METHODS: The 493 
      PTCs samples and 58 tumor-adjacent normal tissues were obtained from The Cancer 
      Genome Atlas database (TCGA). Immune genes were obtained from the ImmPort 
      database. First, this cohort was randomly divided into training cohort and 
      testing cohort. Second, the differentially expressed (DE) immune genes from the 
      training set were used to construct the prognostic model. Then, the testing and 
      entire data cohorts were used to validate the model, and the data were analyzed 
      to determine the correlation of the clinical prognostic model with immune cell 
      infiltration and expression profiles of human leukocyte antigen (HLA) genes. 
      Finally, an analysis of the gene ontology (GO) annotation was performed. RESULTS: 
      A total of 189 upregulated and 128 downregulated DE immune genes were identified. 
      We developed and validated a three-immune gene model for PTC that includes Hsp70, 
      NOX5, and FGF23. This model was demonstrated to be an independent prognostic 
      variable. In addition, the overall immune activity of the high-risk group was 
      higher than that of the low-risk group. CONCLUSIONS: We developed and validated a 
      three-immune gene model for PTC that includes HSPA1A, NOX5, and FGF23. This model 
      can be used as a validated tool to predict outcomes in PTC.
CI  - (c) 2021. Italian Society of Endocrinology (SIE).
FAU - Gan, X
AU  - Gan X
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, Guangzhou 
      Medical University, Guangzhou, China.
AD  - Department of Thyroid Surgery, School of Medicine, Guangzhou First People's 
      Hospital, South China University of Technology, Guangzhou, Guangdong, China.
FAU - Guo, M
AU  - Guo M
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, Guangzhou 
      Medical University, Guangzhou, China.
FAU - Chen, Z
AU  - Chen Z
AD  - Department of Thyroid Surgery, School of Medicine, Guangzhou First People's 
      Hospital, South China University of Technology, Guangzhou, Guangdong, China.
FAU - Li, Y
AU  - Li Y
AD  - Department of Thyroid Surgery, School of Medicine, Guangzhou First People's 
      Hospital, South China University of Technology, Guangzhou, Guangdong, China.
FAU - Shen, F
AU  - Shen F
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, Guangzhou 
      Medical University, Guangzhou, China.
AD  - Department of Thyroid Surgery, School of Medicine, Guangzhou First People's 
      Hospital, South China University of Technology, Guangzhou, Guangdong, China.
FAU - Feng, J
AU  - Feng J
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, Guangzhou 
      Medical University, Guangzhou, China.
AD  - Department of Thyroid Surgery, School of Medicine, Guangzhou First People's 
      Hospital, South China University of Technology, Guangzhou, Guangdong, China.
FAU - Cai, W
AU  - Cai W
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, Guangzhou 
      Medical University, Guangzhou, China.
AD  - Department of Thyroid Surgery, School of Medicine, Guangzhou First People's 
      Hospital, South China University of Technology, Guangzhou, Guangdong, China.
FAU - Xu, B
AU  - Xu B
AUID- ORCID: 0000-0001-6384-6685
AD  - Department of Thyroid Surgery, Guangzhou First People's Hospital, Guangzhou 
      Medical University, Guangzhou, China. gzsrmxu@yeah.net.
AD  - Department of Thyroid Surgery, School of Medicine, Guangzhou First People's 
      Hospital, South China University of Technology, Guangzhou, Guangdong, China. 
      gzsrmxu@yeah.net.
LA  - eng
GR  - 20141A011011/Guangzhou medicine and healthcare technology projects/
GR  - 20151A011007/Guangzhou medicine and healthcare technology projects/
GR  - 20161A011008/Guangzhou medicine and healthcare technology projects/
PT  - Journal Article
PT  - Validation Study
DEP - 20210223
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers/*metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Thyroid Cancer, Papillary/genetics/immunology/*pathology
MH  - Thyroid Neoplasms/genetics/immunology/*pathology
MH  - *Transcriptome
OTO - NOTNLM
OT  - Immune gene
OT  - Papillary thyroid carcinoma
OT  - Prognosis
OT  - Risk model
OT  - TCGA
EDAT- 2021/02/24 06:00
MHDA- 2022/01/19 06:00
CRDT- 2021/02/23 12:18
PHST- 2020/09/05 00:00 [received]
PHST- 2021/01/19 00:00 [accepted]
PHST- 2021/02/24 06:00 [pubmed]
PHST- 2022/01/19 06:00 [medline]
PHST- 2021/02/23 12:18 [entrez]
AID - 10.1007/s40618-021-01514-7 [pii]
AID - 10.1007/s40618-021-01514-7 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2021 Oct;44(10):2153-2163. doi: 10.1007/s40618-021-01514-7. 
      Epub 2021 Feb 23.